AdvaMed Wants Across-The-Board Risk-Based Regulation For Diagnostics
This article was originally published in The Gray Sheet
Executive Summary
Under an AdvaMed plan for expanding FDA regulation of diagnostic tests, tests that consist of new or unproven biomarkers on new technology platforms would likely require a pre-market approval application
You may also be interested in...
FDA Dx Office Plans Pilot 510(k) ‘Triage’ Program For Early 2012
FDA’s diagnostics office will begin a pilot program in early 2012 to triage its review of 510(k) submissions based on product risk and application quality.
FDA Dx Office Plans Pilot 510(k) ‘Triage’ Program For Early 2012
FDA’s diagnostics office will begin a pilot program in early 2012 to triage its review of 510(k) submissions based on product risk and application quality.
FDA: Farewell To 510(k) Review For 30 Types Of Low-Risk Diagnostic Tests
FDA plans to exempt 30 types of diagnostic tests and radiology accessories from 510(k) review in one fell swoop, citing well-established safety and effectiveness profiles for the products.